Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company is headquartered in Rockville, Maryland and currently employs 29 full-time employees. The company went IPO on 2021-02-04. The firm's lead program is PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. The firm is also completing a Phase I/II trial of solnerstotug, its V-domain Ig suppressor of T cell activation (VISTA) inhibitor, in patients with advanced solid tumors. Its TMAb platform is designed to enable highly selective targeting through conditional antibody activation of immune cells in the tumor microenvironment without on-target, off-tumor activity. Its programs include Solnerstotug (SNS-101), SNS-102, SNS-103, and SNS-201. Solnerstotug is a conditionally active, human monoclonal IgG1 antibody designed to block the VISTA checkpoint, which acts as a suppressor of T cells by binding the receptor PSGL-1.
Mr. Christopher Gerry es el President de Sensei Biotherapeutics Inc, se unió a la empresa desde 2025.
¿Qué tal es el rendimiento del precio de la acción SNSE?
El precio actual de SNSE es de $19.6, ha disminuido un 1.1% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Sensei Biotherapeutics Inc?
Sensei Biotherapeutics Inc pertenece a la industria Biotechnology y el sector es Health Care
¿Cuál es la capitalización bursátil de Sensei Biotherapeutics Inc?
La capitalización bursátil actual de Sensei Biotherapeutics Inc es $26.2M
¿Es Sensei Biotherapeutics Inc una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 3 analistas han realizado calificaciones de análisis para Sensei Biotherapeutics Inc, incluyendo 3 fuerte compra, 3 compra, 2 mantener, 0 venta, y 3 fuerte venta
